Phio Pharmaceuticals' $2.5M Warrant Exercise: A Strategic Move to Fuel Clinical Development and Strengthen Liquidity

**

In July 2025, Phio Pharmaceuticals (NASDAQ: PHIO) executed a strategic capital raise through the exercise of 928,596 warrants, generating approximately $2.5 million in gross proceeds. This move, combined with a robust cash position and cost-cutting measures, has positioned the clinical-stage biopharma firm to advance its lead siRNA candidate, PH-762, through the critical Phase 1b immuno-oncology trial while maintaining financial flexibility.

Liquidity Boost and Capital Structure Optimization

The warrant exercise, which included 100,000 shares at $2.00/share and 828,596 shares at a reduced price of $2.485/share, provided Phio with immediate liquidity. The gross proceeds of $2.5 million, before deducting fees, were further enhanced by an additional $232,149 from warrant holders who received new unregistered warrants to purchase 1,857,192 shares of common stock. These new warrants, exercisable at $2.485/share, are split into two tranches: 1,538,596 shares with a 24-month term and 318,596 shares with a 5-year term. This structure offers Phio flexibility while providing investors with long-term upside potential.

Phio's cash reserves had already been bolstered by $9.2 million in registered direct offerings and $2.9 million from previous warrant exercises, bringing the company's cash position to $13.3 million as of March 31, 2025. The recent $2.5 million raise further strengthens this liquidity position, ensuring Phio can fund its operations and clinical development without immediate dilution concerns.

Cost Management and Burn Rate Reduction

Phio has demonstrated disciplined financial management, reducing its burn rate significantly. For the first quarter of 2025, the company reported a net loss of $1.8 million, a 18% improvement from $2.2 million in the same period of 2024. This reduction is attributed to a 23% decrease in research and development (R&D) expenses and a 7% reduction in general and administrative (G&A) expenses. The company has achieved these savings through strategic cost-cutting measures, including relocating to a smaller laboratory facility and terminating non-essential agreements such as its Clinical Co-Development Agreement with AgonOx, Inc.

Funding the Phase 1b Trial for PH-762

Phio's lead candidate, PH-762, is currently in a Phase 1b trial for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. As of March 31, 2025, 15 patients had been treated across four dose cohorts, with the fourth cohort currently enrolling and the fifth expected to be the final one. The trial has reported no dose-limiting toxicities and early signs of efficacy, with some patients achieving complete or partial tumor clearance.

The company has stated that its current capital position, including the recent $2.5 million raise, is sufficient to complete the treatment phase of the Phase 1b trial. Phio has also secured a drug substance development services agreement with a U.S.-based manufacturer for cGMP production of PH-762, further preparing the compound for potential commercialization.

Strategic Positioning in the Biotech Sector

Phio's strategic capital raises and cost rationalization efforts have not only improved its liquidity but also reinforced its long-term positioning in the biotech sector. The company's focus on siRNA therapeutics using its proprietary INTASYL® gene silencing technology has yielded a strong intellectual property portfolio with 77 issued patents. This proprietary technology, combined with the favorable safety and preliminary efficacy data from the PH-762 trial, positions Phio to become a key player in the immuno-oncology space.

Investment Considerations

While Phio's recent financial moves and clinical progress are encouraging, investors should be mindful of the risks inherent in clinical-stage biotech companies. The success of PH-762 in Phase 1b is critical, and the company will need to continue securing capital for later-stage trials and commercialization. However, Phio's disciplined approach to cost management and its focus on high-value clinical programs make it an attractive long-term investment for those comfortable with the biotech risk profile.

The company's ability to advance PH-762 through the Phase 1b trial without immediate dilution, combined with its strong cash reserves and strategic partnerships, suggests that Phio is well-positioned to deliver value to shareholders in the coming years.

Conclusion

Phio Pharmaceuticals' recent $2.5 million warrant exercise, coupled with its cost-cutting measures and strategic capital raises, has significantly strengthened its liquidity and financial flexibility. The company is now well-positioned to advance its lead siRNA candidate, PH-762, through the Phase 1b trial and potentially into later-stage development. With its proprietary INTASYL® technology, strong patent portfolio, and favorable clinical data, Phio represents a compelling investment opportunity in the biotech sector for those seeking exposure to innovative immuno-oncology therapeutics.